| |
April 2023 Clinical Update: NCCN Guidelines for Treatment of Pancreatic Cancer
| |
The National Comprehensive Cancer Network (NCCN) Guidelines for Pancreatic Cancer focus on the screening, diagnosis, staging, treatment, and management considering individual risk assessment.
These updated guidelines include criteria for further genetic risk evaluation using a germline cancer panel for hereditary cancer syndromes: · ANY patient with confirmed pancreatic cancer with no family history or age requirement
Germline testing should be considered in appropriate individuals where it will likely impact the treatment, clinical trial options and risk management. The recommended panels should contain BRCA1, BRCA2, ATM, PALB2, CHEK2, MLH1, MSH2, MSH6, PMS2, CDKN2A, TP53, and STK11.
Genetics Institute of America’s GIAnomics™ Oncology Germline Panel includes all the recommended predisposition genes for Pancreatic Cancer. GIA is committed to exceeding the standards put forth by prestigious organizations, like NCCN, and ensuring that the panels we offer support your medical needs and your patient’s health and safety. | |
| |
Have you Seen This?:
Clinical Implications of Germline Testing in Pancreatic Cancer
According to the National Cancer Institute (NCI), there will be almost 65,000 new cases of pancreatic cancer diagnosed this year within the United States. Unfortunately, NCI also reports an approximate five-year survival rate of 12.5% for those pancreatic cancer patients. Read more >> | | | |
It's All in the Genes:
Impact of Hereditary Cancer Panels on Patient Management
“Multigene panels have become clinically available and commonly ordered because they address syndrome overlap and more effectively identify individuals with PVs than testing for PVs using a single-syndrome approach.”1 Read more >>
| | | |
Changing Corporate Culture:
Biking For Orphans Across the World
To take another needed step towards every child having a loving home, Genetics Institute of America was a presenting sponsor at the Ride for Orphans on Saturday, April 22nd bringing light and hope to orphans all over the world. Read more >> | | | |
| |
| |
Enroll your Practice in GH-101! | |
Genetics Institute of America is actively recruiting practices to join our study, GH-101! The objective of this study is to take an integrative approach to the fields of pharmacogenomics, cancer genomics, mRNA microarrays and nutrigenomics by identifying DNA and RNA variants in persons with chronic disease. We are looking for Physicians and Physician Groups that currently treat patients with a chronic disease including: cancer, cardiac conditions, diabetes, kidney disease, PTSD. Getting your practice involved is easy and not only gets patients the individualized health information they need but allows your practice to be on the cutting edge of genetic research. | |
| |
| |
Thank you for the trust and confidence you have placed in our team here at the Genetics Institute of America. This monthly newsletter is our primary method of communicating to you important information about our testing and assays, general information about the Genetics Institute, as well as information impacting patient care and safety. If you would like to have another person in your practice receive these updates, please forward this to them so that they can subscribe.
 Ana Perez-Miranda, PhD, MDxT (AAB), MB (ASCP) Laboratory Manager and Molecular Diagnostics Supervisor Genetics Institute of America | | | |
| |
| |
| |
GIA Lab News is an educational service of Genetics Institute of America.
Genetics Institute of America is a national laboratory dedicated to heightening the awareness of early intervention and genetic screening to promote the longevity and quality of life outcomes. Our determination and research allow us to provide next generation DNA sequencing to deliver customized testing for identified genetic related cancers and other diseases. | |
| |
| |
4733 W. Atlantic Ave, Suite C16 Delray Beach, FL 33445 Phone: (833) 4GENLAB or (833) 443-6522 HIPAA Fax: (561) 354-5369
| |
You are receiving this email because you opted into receiving communications from Genetics Institute of America online or verbally on the phone, and/or maintain a professional relationship with our laboratory. From time to time, we’ll send newsletters, blog articles, and other educational clinical updates to our subscribers. We hope you find them useful. If not, you can unsubscribe from our list here.
Who do you know that needs to know? Forward this email Did someone forward this to you? Subscribe
Want to change how you receive these emails?
You can Unsubscribe or Update your preferences.
© 2023 Genetics Institute of America. All Rights Reserved.
| |
| |
.png)
